Dermatologic treatment of cutaneous graft versus host disease

American Journal of Clinical Dermatology

Volumn 5, Issue 6, 2004, Pages 403-416

  Peñas, Pablo F ^a   Fernández Herrera, Jesús ^a   García Diez, Amaro ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EMOLLIENT AGENT; ETANERCEPT; ETRETINATE; HALOFUGINONE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INOLIMOMAB; KETOTIFEN; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD147; MONOCLONAL ANTIBODY CD2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; PSORALEN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE CLASSIFICATION; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKODERMA; LICHENOID ERUPTION; LOW DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; RASH; REVIEW; SKIN MANIFESTATION; SKIN ULCER; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION;

CLINICAL TRIALS; ETRETINATE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PUVA THERAPY; SKIN DISEASES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 12944324193     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405060-00005     Document Type: Review

References (126)

1. Johnson ML, Fariner ER. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998; 38: 369-921
2. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 1998; 134 (5): 602-12
3. Ryan LG. Topical armamentarium in the management of acute and chronic graft-versus-host disease. J Pediatr Oncol Nurs 1997; 14 (4): 239-51
4. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29 (3): 259-77
5. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5 (6): 347-56
6. Valks R, Fernandez-Herrera J, Bartolome B, et al. Late appearance of acute graft-vs-host disease after suspending or tapering immunosuppressive drugs. Arch Dermatol 2001; 137 (1): 61-5
7. Fernandez-Herrera J, Valks R, Feal C, et al. Induction of hyperacute graft-vs-host disease after donor leukocyte infusions. Arch Dermatol 1999; 135 (3): 304-8
8. Horn TD, Zahurak ML, Atkins D, et al. Lichen planus-like histopathologic characteristics in the cutaneous graft-vs-host reaction: prognostic significance independent of time course after allogeneic bone marrow transplantation. Arch Dermatol 1997; 133 (8): 961-5
9. Ratanatharathorn V, Ayash L, Lazarus HM, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001; 28 (2): 121-9
10. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74 (4): 1428-35
11. Peñas PF, Jones-Caballero M, Aragües M, et al. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002; 138 (7): 924-34
12. Andrews ML, Robertson I, Weedon D. Cutaneous manifestations of chronic graft-versus-host disease. Australas J Dermatol 1997; 38 (2): 53-62
13. Farmer ER. Human cutaneous graft-versus-host disease. J Invest Dermatol 1985; 85: 124S-128
14. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97 (5): 1219-26
15. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86 (9): 3604-9
16. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25 (10): 1067-71
17. Lee SJ, Klein JP, Barren AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100 (2): 406-14
18. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100 (2): 415-9
19. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 23 (9): 881-7
20. Greinix HT, Volc-Platzer B, Knobler R. Criteria for assessing chronic GVHD [comment). Bone Marrow Transplant 2000; 25 (5): 575
21. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73 (6): 1729-34
22. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81 (4): 1094-101
23. Kroger N, Zabelina T, Kruger W, et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29 (8): 683-9
24. Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196 (3): 389-99
25. Ogawa H, Soma T, Hosen N, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 2002; 74 (2): 236-43
26. Volc-Platzer B, Stingl G. Cutaneous graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-vs-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker Inc., 1990: 245-53
27. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation; an analysis of clinical risk features and outcome. Blood 1990: 75 (4): 1024-30
28. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6 (4A): 441-7
29. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95 (1): 83-9
30. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8 (1): 40-6
31. Xun CQ, Thompson JS, Jennings CD, et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SClD mice. Blood 1994; 83 (8): 2360-7
32. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285 (5426): 412-5
33. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002; 62 (6): 879-89
34. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8 (7): 387-94
35. Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27 (10): 1059-64
36. Remberger M, Aschan J, Barkholt L, et al. Treatment of severe acute graft-versus-ost disease with anti-thymocyte globulin. Clin Transplant 2001; 15 (3): 147-53
37. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimu.s) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26 (9): 985-91
38. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants: Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995; 15 (6): 885-9
39. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30 (5): 287-95
40. Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998; 30 (8): 4087-9
41. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112 (3): 820-3
42. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30 (12): 899-903
43. Couriel DR, Hicks K, Giralt S, et al. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 2000; 12 (6): 582-7
44. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84 (4): 1342-8
45. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322. a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92 (11): 4066-71
46. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD 147 monoclonal antibody ABX-CBL. Blood 2001; 98 (7): 2052-8
47. Furlong T, Leisenring W, Storb R, et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8 (4): 206-12
48. Wiesmann A, Weller A, Lischka G, et al. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Bone Marrow Transplant 1999; 23 (2): 151-5
49. Grundmann-Kollmann M, Martin H, Ludwig R, et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002; 74 (11): 1631-3
50. Dali'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6 (4): 296-304
51. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41 (10): 1299-305
52. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96 (7): 2426-31
53. Bacigalupo A, van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983; 46 (3): 125-32
54. Deeg HJ, Loughran Jr TP, Storb R, et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40 (2): 162-6
55. Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974; 44 (1): 56-75
56. Doney KC, Weiden PL, Storb R, et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing anti-thymocyte globulin and corticosteroids. Am J Hematol 1981; 11 (1): 1-8
57. Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6 (1): 1-8
58. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58 (4): 437-42
59. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14 (4): 601-7
60. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92 (7): 2288-93
61. Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment: a prospective randomized trial. Transplantation 1993; 56 (3): 577-80
62. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77 (8): 1821-8
63. Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19 (8): 759-64
64. Jacobsohn DA. Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 2002; 11 (9); 1271-80
65. Chao NJ. Treatment of acute GVHD. In: Graft versus host disease. 2nd ed. Austin (TX): RG Landes Co, 1999: 103-8
66. Hsu B, May R, Carrum G, et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28 (10): 945-50
67. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98 (10): 2942-7
68. Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8 (3): 155-60
69. Mollee P, Morton AJ, Irving I, et al. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 2001; 113 (1): 217-23
70. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000; 14 (4): 190-204
71. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 2001; 33 (3): 2121-3
72. Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody: a multicenter phase III study. Transplantation 1995; 60 (9): 939-42
73. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72 (12): 1924-9
74. Aubin F, Brion A, Deconinck E, et al. Phototherapy in the treatment of cutaneous graft-versus-host disease: our preliminary experience in resistant patients. Transplantation 1995; 59 (1): 151-5
75. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50 (5): 807-11
76. Bonanomi S, Balduzzi A, Tagliabue A, et al. Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease. Bone Marrow Transplant 2001; 28 (6): 631-2
77. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92 (9): 3098-104
78. Zecca M, Locatelli F. Management of graft-versus-host disease in paediatric bone marrow transplant recipients. Paediatr Drugs 2000; 2 (1): 29-55
79. Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant 1990; 5: 69-82
80. Chosidow O, Bagot M, Vernant JP, et al. Sclerodermatous chronic graft-versus-host disease: analysis of seven cases. J Am Acad Dermatol 1992; 26 (1): 49-55
81. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998; 22 (9): 873-81
82. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in fifty-two patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-76
83. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-38
84. Goerner M, Gooley T, Flowers ME, et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8 (1): 47-56
85. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7 (5); 265-73
86. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6 (6): 613-20
87. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24 (5): 517-20
88. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000; 26 (8): 865-9
89. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73 (4): 665-7
90. Nagler A, Segal V, Slavin S, et al. Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts. Clin Exp Immunol 1995; 100 (3): 529-35
91. Lee SJ, Wegner SA, McGarigle CJ, et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997; 89 (7): 2298-302
92. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6 (3A): 327-34
93. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17 (6): 1061-7
94. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98 (5): 1622-5
95. Rossetti F, Dall'Amico R, Crovetti G, et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant 1996; 18 Suppl. 2: 175-81
96. Bisaccia E, Palangio M, Gonzalez J, et al. Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy. Bone Marrow Transplant 2003; 31 (4): 291-4
97. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003; 31 (6): 459-65
98. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93 (1): 66-70
99. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72 (2): 546-54
100. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97 (5): 1196-201
101. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72 (2): 555-61
102. Gaziev D, Galimberti M, Lucarelli G, et al. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000; 25 (7): 689-96
103. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22 (1): 61-5
104. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001; 27 (12): 1255-62
105. Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2 (2): 86-92
106. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96 (12): 3995-6
107. Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991; 127 (11): 1673-8
108. Volc-Platzer B, Honigsmann H, Hinterberger W, et al. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1990; 23 (2 Pt 1): 220-8
109. Luftl M, Degitz K, Plewig G, et al. Psoralen bath plus UV-A therapy: possibilities and limitations. Arch Dermatol 1997; 133 (12): 1597-603
110. Leiter U, Kaskel P, Krahn G, et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed 2002; 18 (4): 183-90
111. Enk CD, Elad S, Vexler A, et al. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998; 22 (12): 1179-83
112. Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003; 25 (7): 584-8
113. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001; 137 (9): 1202-6
114. Atkinson K. Treatment of extensive human chronic graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-vs-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker Inc., 1990: 681-90
115. Gaziev D, Lucarelli G, Polchi P, et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. Bone Marrow Transplant 2001; 27 (1): 45-51
116. Vogelsang GB. Thalidomide treatment for graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, et al., editors. Graft-vs-host disease: immunology, pathophysiology, and treatment. New York: Marcel Dekker Inc., 1990: 293-300
117. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46 (5): 799-800
118. Grundmann-Kollmann M, Behrens S, Gruss C, et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42 (1 Pt 1): 134-6
119. Dall'Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97 (4): 848-54
120. D'Incan M, Kanold J, Halle P, et al. Extracorporeal photopheresisas an alternative therapy for drug-resistant graft versus host disease: three cases [in French]. Ann Dermatol Venereol 2000; 127 (2): 166-70
121. French LE, Alcindor T, Shapiro M, et al. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30 (8): 509-15
122. Voltarelli JC, Ahmed H, Paton EJ, et al. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion. Bone Marrow Transplant 2001; 28 (1): 97-9
123. Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49 (3): 657-8
124. Currie DM, Ludvigsdottir GK, Diaz CA, et al. Topical treatment of sclerodermoid chronic graft vs host disease. Am J Phys Med Rehabil 2002; 81 (2): 143-9
125. Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999; 68 (11): 1806-9
126. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13 (5): 1091-112, viix